NDA 021688 · Amgen
Sensipar
Cinacalcet Hydrochloride · Oral
NovelPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Mar 8, 2004
Approved uses
4
Original approval plus efficacy supplements
Registered trials
73
23 Phase 3, 2 recruiting
FAERS reports
46,374
16,981 serious, 2,520 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 7, 2025.
Sensipar is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Limitations of Use: Sensipar is not indicated for use in patients with CKD who are not on dialysis Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). ( 1.2 ) Hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. ( 1.3 ) 1.1 Secondary Hyperparathyroidism Sensipar is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis [see Clinical Studies ( 14.1 )]. Limitations of Use: Sensipar is not indicated for use in patients with CKD who are not on dialysis because of an increased risk of hypocalcemia [see Warnings and Precautions ( 5.1 )] . 1.2 Parathyroid Carcinoma Sensipar is indicated for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma [see Clinical Studies ( 14.2 )] . 1.3 Primary Hyperparathyroidism Sensipar is indicated for the treatment of hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy [see Clinical Studies ( 14.3 )] .
Mechanism: The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, is a calcimimetic agent that directly lowers PTH levels by increasing the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 23, 2017 Supplement 23 · Efficacy OrphanLetterLabelPediatric CDTL Review
- Nov 21, 2014 Supplement 21 · Efficacy LabelLetter
- Feb 25, 2011 Supplement 15 · Efficacy OrphanLetterLabel
- Mar 8, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
3 products under this application
- SENSIPAR · CINACALCET HYDROCHLORIDE EQ 90MG BASE · TABLET, ORAL · Discontinued · TE AB
- SENSIPAR · CINACALCET HYDROCHLORIDE EQ 30MG BASE · TABLET, ORAL · Discontinued · TE AB
- SENSIPAR · CINACALCET HYDROCHLORIDE EQ 60MG BASE · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Cinacalcet" as an intervention, any sponsor and status, largest first.
- E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular EventsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00345839 · 3,883 participants · Start Aug 22, 2006 · Primary completion Apr 10, 2012
Drug: Cinacalcet; Placebo · For: Secondary Hyperparathyroidism; Chronic Kidney Disease
- Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00110929 · 850 participants · Start Nov 2002
Drug: AMG 073 · For: End Stage Renal Disease
Kyowa Kirin China Pharmaceutical Co., Ltd.Industry
NCT03123406 · 750 participants · Start Apr 19, 2017 · Primary completion Apr 20, 2019
Drug: Cinacalcet HCl · For: Hyperparathyroidism; Secondary, Renal
Sites: Nanjing, China
- Head-to-Head Study of Etelcalcetide (AMG 416) and CinacalcetPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01896232 · 683 participants · Start Aug 13, 2013 · Primary completion Nov 12, 2014
Drug: Etelcalcetide; Cinacalcet and 2 more · For: Secondary Hyperparathyroidism; Chronic Kidney Disease
Sites: Azusa, California; Bakersfield, California; Chula Vista, California · 182 sites in all
- SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary HyperparathyroidismPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00117052 · 673 participants · Start Sep 2004 · Primary completion Nov 2005
Drug: cinacalcet · For: Secondary Hyperparathyroidism; End Stage Renal Disease
- Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03299244 · 637 participants · Start May 15, 2018 · Primary completion Apr 8, 2020
Drug: Etelcalcetide; Cinacalcet · For: Secondary Hyperparathyroidism; Chronic Kidney Disease
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 90 sites in all
- Phase 3 Study of KHK7580Pivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT02549391 · 634 participants · Start Sep 2015 · Primary completion Nov 2016
Drug: KHK7580; KRN1493 · For: Secondary Hyperparathyroidism
Sites: Tokyo, Japan
- A Research Study for Patients With End-Stage Renal Disease (ESRD)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00110890 · 552 participants · Start May 2004 · Primary completion Apr 2005
Drug: cinacalcet · For: End Stage Renal Disease
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dose omission8,738
- hospitalisation6,929
- laboratory test abnormal4,222
- off label use2,501
- nausea2,285
- intentional product misuse2,084
- death1,834
- malaise1,563
- vomiting1,546
- adverse drug reaction1,461
- diarrhoea1,137
- decreased appetite828
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 104 |
| 2005 | 127 |
| 2006 | 221 |
| 2007 | 121 |
| 2008 | 269 |
| 2009 | 317 |
| 2010 | 399 |
| 2011 | 509 |
| 2012 | 531 |
| 2013 | 789 |
| 2014 | 1,009 |
| 2015 | 7,880 |
| 2016 | 7,587 |
| 2017 | 10,651 |
| 2018 | 12,675 |
| 2019 | 773 |
| 2020 | 388 |
| 2021 | 329 |
| 2022 | 446 |
| 2023 | 413 |
| 2024 | 422 |
| 2025 | 287 |
| 2026 | 127 |
Recalls
3 FDA enforcement reports for this application.
Jun 4, 2026 · Class II · Ongoing
CGMP Deviations
Jun 4, 2026 · Class II · Ongoing
CGMP Deviations
Jun 4, 2026 · Class II · Ongoing
CGMP Deviations
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sensipar (Cinacalcet HCl)
2024 spending
$1.3M
Beneficiaries
233
755 claims
Per beneficiary
$5,634
$33.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $24,137,137 |
| 2021 | $6,666,170 |
| 2022 | $4,084,303 |
| 2023 | $2,727,699 |
| 2024 | $1,312,813 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- End-stage renal disease.
Abbasi MA, Chertow GM, Hall YN · BMJ Clin Evid 2010 · Systematic Review
- Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA, Bushinsky DA, Cheng S, et al. · JAMA 2017 · Clinical Trial, Phase III, Multicenter Study
- The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ye Z, Silverberg SJ, Sreekanta A, et al. · J Bone Miner Res 2022 · Meta-Analysis, Systematic Review
- End stage renal disease.
Hall YN, Chertow GM · BMJ Clin Evid 2007 · Systematic Review
- Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.
Shigematsu T, Asada S, Endo Y, et al. · PLoS One 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
Nakai K, Kono K, Yamada S, et al. · Ther Apher Dial 2024 · Systematic Review, Meta-Analysis
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.